Evolution of <i>AR</i> and Non- <i>AR</i> Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
José C. Valentín López(University of Minnesota), Scott M. Dehm(University of Minnesota)
Cited by 1
Related Papers
Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
|Nucleic Acids Research|2015|151
Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells
|Journal of Biological Chemistry|2006|113